

**Panel on Health Services**

**List of follow-up actions**

(Position as at 15 January 2015)

<b>Subject</b>	<b>Date of meeting</b>	<b>Follow-up action required</b>	<b>Administration's response</b>
1. Regulation and control of pharmaceutical products in Hong Kong	31 March 2009	The Administration was requested to provide the revised checklist used by the inspectors of the Department of Health ("DH") when conducting inspections on pharmaceutical manufacturers once they were finalized.	The Review Committee on Regulation of Pharmaceutical Products in Hong Kong recommended DH in January 2010 to upgrade Hong Kong's current Good Manufacturing Practices ("GMP") licensing standards by a phased approach to the international standards promulgated by the World Health Organization and Pharmaceutical Inspection Co-operation Scheme ("PIC/S"). On DH's invitation, PIC/S conducted a gap assessment between the standards of GMP and PIC/S in end-2010. DH procured a consultancy service in July 2012 for advice on upgrading the current GMP licensing standards to PIC/S standards. The consultancy was completed in late 2014 and the inspection checklist has been revised in accordance with the advice of the consultant. The revised inspection checklist will be submitted to the Panel for reference as soon as possible.

Subject	Date of meeting	Follow-up action required	Administration's response
<p>2. Creation of new directorate posts in DH</p>	<p>11 April 2011</p>	<p>The Administration was requested to report on a quarterly or bi-annual basis the progress in taking forward the recommendations of the Review Committee on the Regulation of Pharmaceutical Products in Hong Kong after the establishment of the Office on Drugs.</p>	<p>The Assistant Director (Drug) and one Chief Pharmacist posts were created on 1 and 14 September 2011 respectively for the setting up of the Drug Office to take forward the recommendations of the Review Committee on the Regulation of Pharmaceutical Products in Hong Kong ("Review Committee").</p> <p>The Administration consulted the Panel on 18 November 2013 in relation to the legislative proposals to implement some of the Review Committee's recommendations, which sought to enhance the regulation of pharmaceutical products. The Administration also attended special meetings of the Panel respectively on 10 December 2013 and 10 February 2014 to exchange views with deputations and Members on the legislative proposals.</p> <p>The Administration introduced the legislative proposals, i.e. the Pharmacy and Poisons (Amendment) Bill 2014, into the Legislative Council on 26 March 2014. At the House Committee of the Legislative Council on 28 March 2014, Members formed a Bills Committee to study the Bill. The Bills Committee has completed the</p>

Subject	Date of meeting	Follow-up action required	Administration's response
			scrutiny of the Bill. The Administration has given notice to resume the Second Reading debate on the Bill at the Council meeting of 21 January 2015.
3. Pilot project on enhancing radiological investigation services through collaboration with the private sector	12 December 2011	The Administration was requested to provide data on the average waiting time of cancer patients for radiological investigation services before and six months after implementation of the pilot project.	The Administration will provide a response in due course.
4. An overview of the re-development and expansion plans of public hospitals	15 July 2013	The Administration was requested to provide a breakdown of the catchment population, the number of beds per 1 000 population, the range of services (including those services that had yet been provided because of manpower constraint or other reasons, and the respective proportion of services provided to patients within and outside the catchment area of the hospital cluster concerned), the manpower shortfall of doctors and nurses, as well as the anticipated changes in the above areas for the next fifteen years (at five-year intervals), by hospital clusters.	The Administration will provide a response in due course.

Subject	Date of meeting	Follow-up action required	Administration's response
<p>5. Mechanism of the Hospital Authority to ensure safety in the use of medical equipment and products</p>	<p>20 October 2014</p>	<p>The Administration was requested to provide -</p> <ul style="list-style-type: none"> <li>(a) detailed information to elaborate on the measures implemented by the Hospital Authority ("HA") at the corporate level to ensure safety in the use of medical equipment and products as set out in paragraph 5 of the Administration's paper (LC Paper No. CB(2)2059/13-14(01)), and the monitoring mechanism in place to ensure that the established guidelines were followed; and</li> <li>(b) a summary of the findings and recommendations of the Root Cause Analysis Panel on the incident concerning the use of expired surgical sutures at the Queen Elizabeth Hospital.</li> </ul>	<p>The Administration will provide a response in due course.</p>
<p>6. Quality management of pathology reports in HA</p>	<p>17 November 2014</p>	<p>The Administration was requested to provide information on -</p> <ul style="list-style-type: none"> <li>(a) the number of disciplinary actions taken by HA against its doctors arising from sentinel events</li> </ul>	<p>The Administration will provide a response in due course.</p>

<b>Subject</b>	<b>Date of meeting</b>	<b>Follow-up action required</b>	<b>Administration's response</b>
		<p>reported to HA Head Office in the past five years, and among these doctors, the number of those who were referred to the Medical Council of Hong Kong for investigation as to whether or not a disciplinary inquiry should be conducted;</p> <p>(b) the establishment and the actual strength of pathologists of the pathology departments of the United Christian Hospital and other public hospitals; and</p> <p>(c) the percentage of audit check on pathology reports issued under the forensic pathology service of the Department of Health.</p>	